Literature DB >> 22044920

Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants.

Kenshi Takechi1, Katsuya Suemaru, Hiromu Kawasaki, Hiroaki Araki.   

Abstract

In clinical practice, patients with epilepsy are frequently associated with psychiatric disorders, including cognitive impairment, depression, and attention deficit hyperactivity disorder. In fact, patients with epilepsy often take centrally acting drugs, such as antidepressants and anxiolytics; however, it remains unclear whether epilepsy is associated with psychiatric function. The present study examined the effect of kindled epileptic seizures on depression-like behavior in mice. The immobility time of pentylenetetrazol-kindled mice was as long as the immobility time of the controls in both a forced swimming test and a tail suspension test. Bupropion (10mg/kg, i.p.) decreased the duration of immobility in the forced swimming test of pentylenetetrazol-kindled mice, while having no significant effect in controls. Furthermore, atomoxetine (2mg/kg, i.p.) caused a significant decrease in the duration of immobility in the tail suspension test of the pentylenetetrazol-kindled mice, while having no significant effect in controls. Using immunohistochemistry, it was shown that there was no significant change in dopamine transporter levels in the striatum; however, norepinephrine transporter was significantly increased in the perirhinal cortex of the pentylenetetrazol-kindled mice. These results suggested that bupropion (in low doses) and atomoxetine are good candidates for the treatment of patients with epilepsy who suffer from psychiatric symptoms. Furthermore, this mechanism may be involved in the change of norepinephrine transporter expression, at least in the perirhinal cortex.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044920     DOI: 10.1016/j.ejphar.2011.10.017

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

2.  Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.

Authors:  Akihiro Tanaka; Kenshi Takechi; Shinichi Watanabe; Mamoru Tanaka; Katsuya Suemaru; Hiroaki Araki
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

Review 3.  Rhythm and blues: animal models of epilepsy and depression comorbidity.

Authors:  S Alisha Epps; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2012-08-23       Impact factor: 5.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.